Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Friedreich ataxia and hereditary ataxias

Neurology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Recognise Friedreich ataxia and other inherited ataxia patterns, choose genomic tests that detect repeat expansions, and coordinate syndrome-specific cardiac, endocrine, neurological and family care.

  • Friedreich ataxia is usually autosomal recessive and caused by biallelic GAA repeat expansions in FXN, reducing frataxin and impairing mitochondrial iron–sulfur biology.
  • Typical disease begins in childhood or adolescence with progressive gait and limb ataxia, dysarthria, impaired vibration and joint position, absent lower-limb reflexes and extensor plantar responses.
  • Look beyond neurology: hypertrophic or fibrotic cardiomyopathy, arrhythmia, scoliosis, pes cavus, diabetes, hearing impairment and optic neuropathy materially affect surveillance and prognosis.
  • The combination of areflexia from peripheral neuropathy and upgoing plantar responses from corticospinal disease is a classic localisation clue in Friedreich ataxia.
  • Autosomal dominant spinocerebellar ataxias often show vertical transmission and age-related anticipation, but de novo disease, reduced penetrance and small families can obscure the pedigree.
  • RFC1 biallelic repeat expansion commonly underlies late-onset sensory ataxia, bilateral vestibular areflexia and chronic cough, sometimes grouped as CANVAS.
  • Routine exome or panel sequencing may miss repeat expansions, mitochondrial variants and structural changes; select the assay through an NHS genomic laboratory and ataxia specialist.
  • No single rehabilitation or medicine plan fits every inherited ataxia: treat reversible mimics and syndrome complications, offer genetic counselling and review emerging disease-modifying eligibility through a specialist centre.

Key red flags

Syncope, exertional chest pain, palpitations or breathlessness in suspected Friedreich ataxia requires urgent cardiac assessment for cardiomyopathy or arrhythmia.

Rapid deterioration over weeks, constitutional symptoms or new encephalopathy is atypical for most hereditary ataxias and needs urgent acquired-cause investigation.

Dysphagia, recurrent aspiration, weak cough or weight loss requires prompt swallowing, nutrition and respiratory assessment.

A child with ataxia, recurrent infections and telangiectasia may have a radiosensitive DNA-repair disorder; involve specialist immunology and genetics before avoidable ionising exposure.

A variant of uncertain significance must not be used as a predictive diagnosis in relatives or as sole justification for irreversible treatment.

Investigation priorities

01
FXN repeat-expansion analysisFirst step

Confirm the common molecular cause of Friedreich ataxia and identify biallelic expanded alleles.

Management branches

SUSPECT FAYoung progressive ataxia

A child or young adult has progressive gait ataxia with areflexia, sensory loss or skeletal features.

  1. Document onset, milestones, school and function, perform full cerebellar, sensory, reflex and plantar examination and construct a three-generation pedigree.
  2. Arrange specialist neurology and clinical genetics referral and request FXN repeat-expansion analysis through the NHS genomic pathway.
  3. Obtain baseline ECG, echocardiography, glucose assessment, hearing, vision, spine, foot, swallowing and mobility evaluation.
  4. Give a coordinated diagnosis discussion and rehabilitation plan, and offer carrier and reproductive counselling after molecular confirmation.

Key medicines

Vitamin E for confirmed deficiency ataxiaUse a specialist-prescribed high-dose oral alpha-tocopherol regimen titrated to the specific inherited deficiency, body weight and serum response rather than a routine supplement dose.Confirm the diagnosis and monitor concentrations and bleeding risk, particularly with anticoagulants; vitamin E does not treat genetically unrelated ataxias.
BaclofenStart with a low oral dose, commonly 5 mg up to three times daily, and titrate gradually to function and tolerance under the rehabilitation or neurology plan.Sedation and weakness can worsen transfers and falls; reduce for renal impairment and avoid abrupt withdrawal after established treatment.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NHS England National Genomic Test DirectoriesCurrent commissioned testing and laboratory routes for hereditary ataxias.
  • NHS Genomics Education knowledge hubAuthoritative NHS genomic inheritance and testing education.
  • NICE NG127 suspected neurological conditionsReferral framework for progressive gait and neurological syndromes.
  • NHS clinical overview of ataxiaUK overview of inherited causes, diagnosis and support.
  • BNF baclofen monographUK dosing, renal cautions and withdrawal safety.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom